Verastem, Inc. Files 8-K for Regulatory, Other Events
Ticker: VSTM · Form: 8-K · Filed: Dec 31, 2025 · CIK: 1526119
| Field | Detail |
|---|---|
| Company | Verastem, INC. (VSTM) |
| Form Type | 8-K |
| Filed Date | Dec 31, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulatory-filing, financials
TL;DR
Verastem filed an 8-K on Dec 29th for Reg FD, other events, and financials. Keep an eye on this.
AI Summary
Verastem, Inc. filed an 8-K on December 31, 2025, reporting events that occurred on December 29, 2025. The filing indicates it is for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company is incorporated in Delaware and its principal executive offices are located at 117 Kendrick Street, Suite 500, Needham, MA 02494.
Why It Matters
This 8-K filing signals that Verastem, Inc. is disclosing important corporate events and potentially financial information to the public, which could impact investor understanding of the company's status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for disclosure and does not appear to contain immediate negative news or significant financial distress.
Key Players & Entities
- Verastem, Inc. (company) — Registrant
- December 29, 2025 (date) — Date of earliest event reported
- December 31, 2025 (date) — Filing date
- 117 Kendrick Street, Suite 500, Needham, MA 02494 (location) — Principal Executive Offices
FAQ
What specific events are being disclosed under Regulation FD?
The filing does not specify the exact events covered under Regulation FD disclosure in the provided text.
What are the 'Other Events' being reported by Verastem, Inc.?
The provided text does not detail the specific 'Other Events' that Verastem, Inc. is reporting.
What financial statements and exhibits are included in this 8-K filing?
The filing indicates that Financial Statements and Exhibits are included, but the specific contents are not detailed in the provided excerpt.
When was Verastem, Inc. incorporated and in which state?
Verastem, Inc. was incorporated in Delaware.
What is the business address and phone number for Verastem, Inc.?
The business address is 117 Kendrick Street, Suite 500, Needham, MA 02494, and the telephone number is (781) 292-4200.
Filing Stats: 994 words · 4 min read · ~3 pages · Grade level 12.9 · Accepted 2025-12-30 19:02:25
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share VSTM The Nasdaq
Filing Documents
- tm2534532d1_8k.htm (8-K) — 31KB
- tm2534532d1_ex99-1.htm (EX-99.1) — 27KB
- 0001104659-25-125309.txt ( ) — 229KB
- vstm-20251229.xsd (EX-101.SCH) — 3KB
- vstm-20251229_lab.xml (EX-101.LAB) — 33KB
- vstm-20251229_pre.xml (EX-101.PRE) — 22KB
- tm2534532d1_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On December 29, 2025, Verastem, Inc. (the "Company") issued a press release announcing it will discontinue the RAMP 203 clinical trial in advanced KRAS G12C-mutated non-small cell lung cancer ("NSCLC"). A copy of this press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K.
01 Other Events
Item 8.01 Other Events Recent Developments Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer Following evaluation of interim data from the RAMP 203 clinical trial in advanced KRAS G12C-mutated NSCLC the Company will discontinue the trial to focus resources on clinical development of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in advanced NSCLC and other solid tumors. There will be no further enrollment in RAMP 203 and patients currently enrolled will have the option to continue treatment per investigator discretion. This decision reflects the evolving treatment landscape for KRAS G12C inhibitors and the strategic prioritization of programs with the greatest potential impact for patients living with advanced lung cancer. RAMP 203 is a Phase 1/2 clinical trial being conducted in collaboration with Amgen evaluating avutometinib, an oral rapidly accelerated fibrosarcoma (RAF)/ mitogen-activated protein kinase kinase (MEK) clamp, and LUMAKRAS (sotorasib) in a "doublet combination" and also with defactinib, an oral focal adhesion kinase inhibitor, as a "triplet combination" in patients nave to or previously treated with a KRAS G12C inhibitor. As of November 26, 2025, the data cutoff, 66 patients were treated at the recommended Phase 2 dose, had at least one tumor scan, and were evaluable for efficacy. For the doublet combination, 30 G12C-inhibitor treatment-nave patients were efficacy evaluable and achieved an overall response rate ("ORR") of 40% (12/30) and the median progression-free survival ("PFS") was 11.1 months with a median follow up of 15.9 months. In the previously G12C-inhibitor treated group for the doublet combination, 21 patients were efficacy evaluable and achieved an ORR of 9.5% (2/21) and a median PFS of 3.7 months with a median follow up time of 10.8 months. Among six G12C-inhibitor treatment-nave patients in the triple combination, four were evaluable for efficacy and achieved an ORR of
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release, dated December 29, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERASTEM, INC. Dated: December 30, 2025 By: /s/ Daniel W. Paterson Daniel W. Paterson Chief Executive Officer